ArticleFrontiers in neuroscience2024
Sustained corneal nerve loss predicts the development of diabetic neuropathy in type 2 diabetes.
Article in Frontiers in neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- GLP-1 Receptor Agonists and the Ocular Surface: A Narrative Review of Restoration, Remodeling, and Clinical Implications.Ophthalmology and therapy · 2026Review
- Periodontal Inflammatory Burden and Multi-Organ Microvascular Impairment in Type 2 Diabetes: A Cross-Sectional Observational Study.Current issues in molecular biology · 2026Article
- Corneal Innervation Research at a Crossroads: A Tool-Driven Roadmap for the Future.Investigative ophthalmology & visual science · 2026Review
- Corneal Confocal Microscopy as a Non-Invasive Marker of Small Fiber Neuropathy and Systemic Complications in Type 2 Diabetes: A Cross-Sectional Study.Biomolecules · 2026Observational
- Diabetic dry eye: advances in pathogenesis, diagnostic strategies, and therapeutic approaches.Frontiers in medicine · 2026Review
- Association of the glucose metabolism continuum (fasting plasma glucose/HbA1c) with tear-film stability and secretion: ocular surface evidence across non-diabetes, prediabetes, and diabetes.Frontiers in endocrinology · 2026Article
- Expression of miR-210-3p as a Prognostic Marker for Development of Diabetic Neuropathy.Metabolites · 2025Article
- Methods for the evaluation of corneal nerve fibres in diabetes mellitus by in vivo confocal microscopy: a scoping review.BMJ open · 2025Article
- The Correlation Between Functional and Morphometric Small Fiber Assessment in Mixed Etiology Polyneuropathy.Journal of the peripheral nervous system : JPNS · 2025Article
- Obesity negatively impacts corneal nerves in patients with diabetes mellitus.Eye and vision (London, England) · 2025Article
- Differential Impact of Metabolic Factors and Comorbidities on Peripheral Neuropathy.Journal of the peripheral nervous system : JPNS · 2025Article
- Benefits of Cilostazol's Effect on Vascular and Neuropathic Complications Caused by Diabetes.Medical sciences (Basel, Switzerland) · 2024Review
- Glucose-lowering medication associated with weight loss may limit the progression of diabetic neuropathy in type 2 diabetes.Journal of the peripheral nervous system : JPNS · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study was undertaken to investigate whether sustained rather than a single measure of corneal nerve loss was associated with the onset of diabetic peripheral neuropathy (DPN) and the progression of neuropathic symptoms and deficits in individuals with type 2 diabetes (T2D). Methods: Participants underwent clinical, metabolic testing and assessment of neuropathic symptoms, vibration perception threshold (VPT), sudomotor function, and corneal confocal microscopy (CCM) at baseline, 1, 2, and 4-7 years. Sustained corneal nerve loss was defined as abnormal corneal nerve fiber density (CNFD, <24 fibers/mm Results: A total of 107 participants with a mean duration of T2D of 13.3 ± 7.3 years, aged 54.8 ± 8.5 years, underwent baseline and follow-up assessments over a median duration of 4 years, ranging from 1 to 7 years. The DPN prevalence at baseline was 18/107 (16.8%), and of the 89 participants without DPN at baseline, 13 (14.6%) developed DPN during follow-up. Approximately half of the cohort had sustained corneal nerve damage, and corneal nerve measures were significantly lower in this group than those without sustained damage ( Conclusion: Sustained abnormal CCM is associated with more severe corneal nerve damage, DPN development, and the progression of neuropathic symptoms and deficits. Regular CCM monitoring may enable the identification of those at greater risk of developing and worsening DPN who may benefit from more aggressive risk factor reduction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.